Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities, GMP manufacturing, global vendor management, and people leadership.

“Stefan joins Pharvaris at a transformative time as we prepare to transition into a late-stage clinical company and prepare for commercialization in the coming years,” said Berndt Modig, Chief Executive Officer of Pharvaris. “His experience building sustainable and scalable production strategies for clinical-stage candidates and commercial-grade medicines as well as setting up agile expert teams will be instrumental in the execution of our Phase 3 studies and diligent preparations for commercialization. We welcome Stefan and the insights he will bring to our executive team.”

Dr. Abele added, “Deucrictibant could significantly improve the current standard of care for those living with HAE and Pharvaris is poised to make a meaningful impact on the entire HAE community. To our knowledge, deucrictibant is the only orally bioavailable B2 receptor antagonist in development for the treatment of HAE; I am excited to have the opportunity to join the Pharvaris team and contribute my expertise in the development of this novel therapeutic.”

Previously, Dr. Abele served as the Senior Vice President, Chemical Development and Commercial Manufacturing at Idorsia Pharmaceuticals, where he and his team were responsible for the API development and manufacturing of QUVIVIQ (daridorexant), PIVLAZ (clazosentan), and aprocitentan. Prior to Idorsia, Dr. Abele worked at Actelion Pharmaceuticals where he established and grew the fully integrated Chemistry Process R&D department. Earlier, he held positions of growing responsibility at Carbogen-Amcis, including as Head of Production and as a manager of teams in R&D and GMP manufacturing of APIs for global pharma companies. Dr. Abele holds a Diploma in Chemistry from the University of Konstanz and a Ph.D. in Synthetic Organic Chemistry from the ETH Zurich.